Literature DB >> 7913072

Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.

F S Guimarães1, J C de Aguiar, R Mechoulam, A Breuer.   

Abstract

1. In order to assess the presence of anxiolytic properties in cannabidiol (CBD) derivatives HU-219, HU-252 and HU-261, these drugs were tested in rats submitted to the elevated plus-maze model of anxiety. 2. Additional groups received diazepam or CBD. HU-219 (0.03-1 mg/kg) and CBD (5 mg/kg) significantly increased the percentage of open arm entries without changing the total number of entries, an anxiolytic-like effect. 3. Both HU-252 and HU-261 increased the percentage of time spent in open arms and the total number of entries, but only at the dose of 1 mg/kg. 4. Diazepam (2.5 mg/kg) increased both the percentage of entries and time spent on open arms and the total number of entries. 5. The results confirm previous findings with CBD and indicate that its derivative HU-219 may possess a similar anxiolytic-like profile. 6. Results from HU-252 and HU-261 are less apparent and suggest that the compounds may increase general exploratory activity in a limited range of doses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913072     DOI: 10.1016/0306-3623(94)90027-2

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  22 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

Authors:  Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

Review 3.  High times for cannabis: Epigenetic imprint and its legacy on brain and behavior.

Authors:  Henrietta Szutorisz; Yasmin L Hurd
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 6.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

7.  Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.

Authors:  Yanhua Ren; John Whittard; Alejandro Higuera-Matas; Claudia V Morris; Yasmin L Hurd
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

8.  Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors.

Authors:  Markus Kathmann; Karsten Flau; Agnes Redmer; Christian Tränkle; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-18       Impact factor: 3.000

Review 9.  Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.

Authors:  Yasmin L Hurd; Michelle Yoon; Alex F Manini; Stephanie Hernandez; Ruben Olmedo; Maria Ostman; Didier Jutras-Aswad
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

10.  Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.

Authors:  Deepak Cyril D'Souza; Mohini Ranganathan; Gabriel Braley; Ralitza Gueorguieva; Zoran Zimolo; Thomas Cooper; Edward Perry; John Krystal
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.